ProQR Therapeutics (PRQR)
(Delayed Data from NSDQ)
$2.10 USD
-0.09 (-4.11%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $2.11 +0.01 (0.48%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PRQR 2.10 -0.09(-4.11%)
Will PRQR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PRQR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRQR
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates
Techne (TECH) Q3 Earnings and Revenues Beat Estimates
PRQR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength?
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
Krystal Biotech, Inc. (KRYS) Beats Q3 Earnings and Revenue Estimates
Other News for PRQR
Is PRQR positioned for a breakdown? Non-ADX 1,2,3,4 Bearish shows up after sinking 4.11%
Crossed Above 200 Day Moving Average appears for PRQR after 6.31% move
PRQR rises 3.52% on September 18, leaving the technical picture intact
MACD Bearish Centerline Cross appears for PRQR after 0.25% move
Fell Below 200 Day Moving Average appears for PRQR after 9.36% move